Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Study sponsor: Reviva Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-02Estimated
Enrollment · participants690Estimated
Source updated2024-12-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.